Nektar Therapeutics (NKTR) CEO logs small 444-share tax-related stock sale

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Nektar Therapeutics President & CEO Howard W. Robin reported a small tax-related share sale. On this Form 4, he sold 444 shares of common stock at a weighted average price of $65.51 per share to cover required tax withholding obligations from vesting RSUs, which the company notes was not a discretionary trade.

After the sale, Robin directly holds 75,045 shares of Nektar common stock and has an additional 28 shares reported as indirectly owned through his spouse. The filing reflects routine equity compensation and related tax settlement rather than a change in his overall investment stance.

Insights

CEO’s sale is a small, non-discretionary tax withholding event.

The Form 4 shows Nektar Therapeutics CEO Howard W. Robin sold 444 common shares at a weighted average of $65.51 per share. A footnote clarifies this was solely to cover required tax withholding from vesting RSUs, not a discretionary decision to reduce exposure.

Following the transaction, Robin still directly holds 75,045 shares and indirectly 28 shares through his spouse, so the sale is minor relative to his total position. Because the sale was driven by tax obligations linked to equity compensation, it carries limited informational value about his view of the stock.

Insider Trade Summary

Net Seller: 444 shares ($29,086)

Net Sell 2 txns

Insider ROBIN HOWARD W

Role President & CEO

Sold 444 shs ($29K)

Type	Security	Shares	Price	Value
Sale	Common Stock	444	$65.51	$29K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 75,045 shares (Direct, null); Common Stock — 28 shares (Indirect, by spouse)

Footnotes (1)

Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $64.88 to $68.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.

Key Figures

Shares sold: 444 shares Weighted average sale price: $65.51 per share Share price range: $64.88 to $68.43 +3 more

6 metrics

Shares sold 444 shares Common stock sold to cover RSU tax withholding

Weighted average sale price $65.51 per share Open-market sale on 2026-05-19

Share price range $64.88 to $68.43 Price range of multiple execution trades

Direct holdings after transaction 75,045 shares CEO’s direct Nektar common stock position post-sale

Indirect holdings (spouse) 28 shares Indirect ownership reported as held by spouse

Net buy/sell shares -444 shares Net effect of reported transactions in this Form 4

Key Terms

RSUs, tax withholding obligations, weighted average sale price, multiple trades, +1 more

5 terms

RSUs financial

"in connection with the vesting of the RSUs held by the reporting person"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

tax withholding obligations financial

"sold by the reporting person to cover required tax withholding obligations"

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

multiple trades financial

"This transaction was executed in multiple trades at prices ranging from $64.88 to $68.43."

indirect ownership financial

"total_shares_following_transaction: 28.0000, direct_or_indirect: I, nature_of_ownership: by spouse"

Form 4 Insider Transactions: What Each Field Means →

05/21/2026 - 06:26 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROBIN HOWARD W

(Last)

(First)

(Middle)

C/O NEKTAR THERAPEUTICS

455 MISSION BAY BLVD SOUTH

(Street)

SAN FRANCISCO

CALIFORNIA

94158

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEKTAR THERAPEUTICS [ NKTR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/19/2026		S		444⁽¹⁾	D	$65.51⁽²⁾	75,045	D
Common Stock								28	I	by spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.

2. This transaction was executed in multiple trades at prices ranging from $64.88 to $68.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.

	Elizabeth Zhang, Attorney-in-Fact	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did Nektar Therapeutics (NKTR) report for its CEO?

Nektar Therapeutics reported that CEO Howard W. Robin sold 444 shares of common stock. The shares were sold to cover required tax withholding obligations from vesting RSUs, and not as a discretionary decision to change his economic exposure to the company.

How many Nektar Therapeutics (NKTR) shares did the CEO sell and at what price?

Howard W. Robin sold 444 Nektar Therapeutics common shares. The filing reports a weighted average sale price of $65.51 per share, with individual trades executed between $64.88 and $68.43 according to the accompanying footnote disclosure.

Why did the Nektar Therapeutics (NKTR) CEO sell shares in this Form 4?

The CEO’s sale was to cover required tax withholding obligations tied to vesting RSUs. The company specifies in a footnote that this transaction does not represent a discretionary trade by Howard W. Robin, indicating it was a routine tax-related event.

How many Nektar Therapeutics (NKTR) shares does the CEO hold after this transaction?

After the reported transaction, Howard W. Robin directly holds 75,045 shares of Nektar Therapeutics common stock. The Form 4 also shows an additional 28 shares reported as indirectly owned through his spouse, reflecting a small related holding.

Does the Nektar Therapeutics (NKTR) Form 4 indicate a change in insider sentiment?

The Form 4 primarily reflects a tax-related sale of 444 shares, not a discretionary reduction in holdings. Because the sale covers RSU tax withholding and the CEO retains over 75,000 shares, it appears to be a routine compensation-related transaction rather than a signal of shifting sentiment.